Juvenile treatment with a novel mGluR2 agonist/mGluR3 antagonist compound, LY395756, reverses learning deficits and cognitive flexibility impairments in adults in a neurodevelopmental model of schizophrenia

Meng-Lin Li,Yelena Gulchina,Sarah A. Monaco,Bo Xing,Brielle R. Ferguson,Yan-Chun Li,Feng Li,Xi-Quan Hu,Wen-Jun Gao
DOI: https://doi.org/10.1016/j.nlm.2017.02.004
IF: 3.109
2017-01-01
Neurobiology of Learning and Memory
Abstract:•Gestational MAM exposure induced a significant decrease in NMDAR expression.•LY39 treatment effectively recovers the disrupted NMDAR expression in MAM rats.•Early treatment targeting mGluR2 alleviates learning and cognitive flexibility deficits.•Targeting NMDARs during early stages of SCZ could be an effective strategy.
What problem does this paper attempt to address?